Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
2
×
national blog main
national top stories
new york
2
×
new york blog main
new york top stories
akcea therapeutics
amgen
anylam pharmaceuticals
cardiomyopathy
cholesterol
data
drugs
inclisiran
inotersen
ldl
mark timney
mt sinai hospital
neuropathy
onpattro
patisiran
pcsk9
peter wijngaard
pfizer
praluent
prashant vaishnava
regeneron pharmaceuticals
repatha
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
sanofi
tafamidis
tegsedi
the medicines co.
transthyretin amyloidosis
What
drug
medicines
year
2
×
aces
ago
akcea
alnylam
amyloidosis
announced
approved
attr
available
battle
big
ceo
cholesterol
debilitating
disease
fda
flexible
genetic
inclisiran
key
lowering
meant
medco
medicine
nasdaq
oks
open
passed
patients
pfizer
pricing
rare
sets
taken
test
transthyretin
twice
Language
unset
Current search:
" new york "
×
" life sciences "
×
year
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea